Ovarian response in preimplantation genetic testing for myotonic dystrophy type 1.

Purpose: To evaluate ovarian stimulation response in couples undergoing preimplantation genetic testing (PGT-M) for myotonic dystrophy type 1 (DM1) METHODS: Retrospective, observational, multicentric study. Parameters of ovarian response and PGT-M outcomes were compared according to the DM1-affected patient (female or male). A total of 229 couples underwent at least one controlled ovarian hyperstimulation cycle for the PGT-M procedure.

New Insights on In Vitro Maturation of Oocytes for Fertility Preservation.

In the last decade, the evolution of oncofertility has sparked a resurgence of interest in in vitro maturation (IVM) due to its suitability in certain oncological scenarios where controlled ovarian hyperstimulation may not be feasible. The retrieval of immature cumulus-oocyte complexes from small antral follicles, regardless of the menstrual cycle phase, presents a swift opportunity to vitrify mature oocytes or embryos post-IVM in urgent situations or when stimulation is not advisable. Harvesting immature cumulus-oocyte complexes and immature oocytes can be achieved transvaginally or directly in the laboratory from extracorporeal ovarian tissue.

Effect of breast cancer prognostic factors on ovarian reserve and response in fertility preservation.

Research Question: Do breast cancer prognostic factors influence ovarian reserve and response to ovarian stimulation in the context of fertility preservation?

Design: Observational, bicentric retrospective study of 352 women with breast cancer who underwent ovarian stimulation using a random start gonadotrophin releasing hormone antagonist protocol and vitrified oocytes between November 2015 and August 2022. Serum anti-Müllerian hormone (AMH) levels and antral follicle count (AFC) were measured. The number of oocytes recovered, maturation rate and follicular output rate (FORT) were analysed according to patients' characteristics and breast cancer prognostic factors.

Fertility outcomes several years after urgent fertility preservation for patients with breast cancer.

Objective: To study the fertility outcomes of women who tried to conceive after breast cancer (BC) treatment and fertility preservation.

Design: Retrospective observational, bicentric cohort study.

Setting: University hospital.

Risk factors for poor oocyte yield and oocyte immaturity after GnRH agonist triggering.

Study Question: What are the potential risk factors for poor oocyte recuperation rate (ORR) and oocyte immaturity after GnRH agonist (GnRHa) ovulation triggering?

Summary Answer: Lower ovarian reserve and LH levels after GnRHa triggering are risk factors of poor ORR. Higher BMI and anti-Müllerian hormone (AMH) levels are risk factors of poor oocyte maturation rate (OMR).

What Is Known Already: The use of GnRHa to trigger ovulation is increasing.